# Ernexa Therapeutics Inc.: financial statements, quarterly

ERNA · Nasdaq · CIK 748592 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/erna.md) · [Financials](/companies/erna/financials.md) · [Filings](/companies/erna/filings.md) · [Insiders](/companies/erna/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/erna/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [0.1](/filings/0001493152-24-044841.md) | [0.0 d](/filings/0001493152-25-010051.md) | [0.0](/filings/0001641172-25-009044.md) | [0.0](/filings/0001493152-25-011910.md) | [0.5](/filings/0001493152-25-021287.md) | [0.0 d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Cost of revenue | $m | [0.1](/filings/0001493152-24-044841.md) | [0.1 d](/filings/0001493152-25-010051.md) | [0.1](/filings/0001641172-25-009044.md) | [0.1](/filings/0001493152-25-011910.md) | [(0.1)](/filings/0001493152-24-044841.md) | [0.0 d](/filings/0001493152-26-010102.md) | not reported | [0.0](/filings/0001493152-26-036424.md) | not reported | not reported | not reported | [0.0](/filings/0001493152-26-036424.md) |
| Gross profit | $m | [(0.1)](/filings/0001493152-24-044841.md) | [(0.0) d](/filings/0001493152-25-010051.md) | [(0.0)](/filings/0001641172-25-009044.md) | [(0.0)](/filings/0001493152-25-011910.md) | [0.5](/filings/0001493152-25-021287.md) | [0.0 d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Selling, general and administrative | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(5.5)](/filings/0001493152-24-044841.md) | [(5.8) d](/filings/0001493152-25-010051.md) | [(5.8)](/filings/0001641172-25-009044.md) | [(4.9)](/filings/0001493152-25-011910.md) | [(2.3)](/filings/0001493152-25-021287.md) | [(2.7) d](/filings/0001493152-26-010102.md) | [(2.7)](/filings/0001493152-26-022276.md) | [(2.5)](/filings/0001493152-26-036424.md) | [(2.0)](/filings/0001493152-25-021287.md) | [(2.1) d](/filings/0001493152-26-010102.md) | [(5.6)](/filings/0001493152-26-022276.md) | [(4.1)](/filings/0001493152-26-036424.md) |
| Interest expense | $m | not reported | not reported | [0.1](/filings/0001641172-25-009044.md) | [0.8](/filings/0001493152-25-011910.md) | [1.7](/filings/0001493152-25-021287.md) | [(10.1) d](/filings/0001493152-26-010102.md) | [0.8](/filings/0001641172-25-009044.md) | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [(0.0)](/filings/0001493152-24-044841.md) | [(0.0) d](/filings/0001493152-25-010051.md) | [0.0](/filings/0001641172-25-009044.md) | [0.0](/filings/0001493152-25-011910.md) | [0.0](/filings/0001493152-25-021287.md) | [0.0 d](/filings/0001493152-26-010102.md) | [0.0](/filings/0001493152-26-022276.md) | [0.0](/filings/0001493152-26-036424.md) | [0.0](/filings/0001493152-25-021287.md) | [(0.1) d](/filings/0001493152-26-010102.md) | [(0.0)](/filings/0001493152-26-022276.md) | [0.0 d](/filings/0001493152-26-036424.md) |
| Net income | $m | [(5.6)](/filings/0001493152-24-044841.md) | [(6.2) d](/filings/0001493152-25-010051.md) | [(6.6)](/filings/0001641172-25-009044.md) | [(5.5)](/filings/0001493152-25-011910.md) | [(26.6)](/filings/0001493152-25-021287.md) | [(5.8) d](/filings/0001493152-26-010102.md) | [(8.2)](/filings/0001493152-26-022276.md) | [(3.1)](/filings/0001493152-26-036424.md) | [(1.2)](/filings/0001493152-25-021287.md) | [(1.5) d](/filings/0001493152-26-010102.md) | [(5.5)](/filings/0001493152-26-022276.md) | [(4.0)](/filings/0001493152-26-036424.md) |
| Diluted EPS | $ per share | [(1.03)](/filings/0001493152-24-044841.md) | not reported | [(1.23)](/filings/0001641172-25-009044.md) | [(15.34)](/filings/0001493152-25-011910.md) | [(73.70)](/filings/0001493152-25-021287.md) | not reported | [(57.76)](/filings/0001493152-26-022276.md) | [(15.19)](/filings/0001493152-26-036424.md) | [(0.15)](/filings/0001493152-25-021287.md) | not reported | [(6.95)](/filings/0001493152-26-022276.md) | [(3.40)](/filings/0001493152-26-036424.md) |
| Basic EPS | $ per share | [(1.03)](/filings/0001493152-24-044841.md) | not reported | [(1.23)](/filings/0001641172-25-009044.md) | [(15.34)](/filings/0001493152-25-011910.md) | [(73.70)](/filings/0001493152-25-021287.md) | not reported | [(57.76)](/filings/0001493152-26-022276.md) | [(15.19)](/filings/0001493152-26-036424.md) | [(0.15)](/filings/0001493152-25-021287.md) | not reported | [(6.95)](/filings/0001493152-26-022276.md) | [(3.40)](/filings/0001493152-26-036424.md) |

- Revenue: us-gaap:Revenues
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: not reported
- Selling, general and administrative: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [4.6](/filings/0001493152-24-044841.md) | [7.6](/filings/0001493152-25-010051.md) | [5.1](/filings/0001641172-25-009044.md) | [2.6](/filings/0001493152-25-011910.md) | [4.3](/filings/0001493152-24-044841.md) | [1.7](/filings/0001493152-25-010051.md) | [1.9](/filings/0001641172-25-009044.md) | [4.3](/filings/0001493152-25-011910.md) | [3.0](/filings/0001493152-25-021287.md) | [1.9](/filings/0001493152-26-036424.md) | [9.2](/filings/0001493152-26-022276.md) | [5.0](/filings/0001493152-26-036424.md) |
| Current assets | $m | [7.0](/filings/0001140361-23-052742.md) | [9.6](/filings/0001493152-25-010051.md) | [6.2](/filings/0001140361-24-026010.md) | [3.6](/filings/0001493152-24-031639.md) | [4.7](/filings/0001493152-24-044841.md) | [2.4](/filings/0001493152-26-010102.md) | [2.2](/filings/0001641172-25-009044.md) | [4.8](/filings/0001493152-25-011910.md) | [3.4](/filings/0001493152-25-021287.md) | [3.1](/filings/0001493152-26-036424.md) | [10.0](/filings/0001493152-26-022276.md) | [5.9](/filings/0001493152-26-036424.md) |
| Total assets | $m | [52.2](/filings/0001140361-23-052742.md) | [49.1](/filings/0001493152-25-010051.md) | [49.7](/filings/0001140361-24-026010.md) | [46.5](/filings/0001493152-24-031639.md) | [7.7](/filings/0001493152-24-044841.md) | [5.3](/filings/0001493152-26-010102.md) | [5.1](/filings/0001641172-25-009044.md) | [7.6](/filings/0001493152-25-011910.md) | [6.2](/filings/0001493152-25-021287.md) | [5.8](/filings/0001493152-26-036424.md) | [10.5](/filings/0001493152-26-022276.md) | [6.3](/filings/0001493152-26-036424.md) |
| Current liabilities | $m | [9.6](/filings/0001140361-23-052742.md) | [6.6](/filings/0001493152-25-010051.md) | [7.8](/filings/0001140361-24-026010.md) | [9.6](/filings/0001493152-24-031639.md) | [10.0](/filings/0001493152-24-044841.md) | [2.9](/filings/0001493152-26-010102.md) | [10.4](/filings/0001641172-25-009044.md) | [2.7](/filings/0001493152-25-011910.md) | [2.1](/filings/0001493152-25-021287.md) | [3.1](/filings/0001493152-26-036424.md) | [3.5](/filings/0001493152-26-022276.md) | [2.9](/filings/0001493152-26-036424.md) |
| Total liabilities | $m | [48.7](/filings/0001140361-23-052742.md) | [46.9](/filings/0001493152-25-010051.md) | [53.1](/filings/0001140361-24-026010.md) | [55.0](/filings/0001493152-24-031639.md) | [53.1](/filings/0001493152-24-044841.md) | [3.6](/filings/0001493152-26-010102.md) | [11.0](/filings/0001641172-25-009044.md) | [3.1](/filings/0001493152-25-011910.md) | [2.6](/filings/0001493152-25-021287.md) | [3.4](/filings/0001493152-26-036424.md) | [3.7](/filings/0001493152-26-022276.md) | [3.1](/filings/0001493152-26-036424.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Current portion of debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [3.6](/filings/0001493152-24-044841.md) | [2.2](/filings/0001493152-26-010102.md) | [(3.4)](/filings/0001493152-25-011910.md) | [(8.5)](/filings/0001493152-25-021287.md) | [(45.4)](/filings/0001493152-25-021287.md) | [1.7](/filings/0001493152-26-036424.md) | [(6.0)](/filings/0001493152-26-036424.md) | [4.4](/filings/0001493152-26-036424.md) | [3.6](/filings/0001493152-25-021287.md) | [2.4](/filings/0001493152-26-036424.md) | [6.9](/filings/0001493152-26-036424.md) | [3.2](/filings/0001493152-26-036424.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue, us-gaap:Cash
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Current portion of debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $k | [(5,826) d](/filings/0001493152-24-044841.md) | [(4,661) d](/filings/0001493152-25-010051.md) | [(3,747)](/filings/0001641172-25-009044.md) | [(2,259) d](/filings/0001493152-25-011910.md) | [(6,285) d](/filings/0001493152-25-021287.md) | [(3,545) d](/filings/0001493152-26-010102.md) | [(2,065)](/filings/0001493152-26-022276.md) | [(2,532) d](/filings/0001493152-26-036424.md) | [(1,272) d](/filings/0001493152-25-021287.md) | [(1,148) d](/filings/0001493152-26-010102.md) | [(2,264)](/filings/0001493152-26-022276.md) | [(4,152) d](/filings/0001493152-26-036424.md) |
| Capital expenditure | $k | [0.0 d](/filings/0001140361-23-052742.md) | [19.0 d](/filings/0001493152-25-010051.md) | [101](/filings/0001641172-25-009044.md) | [249 d](/filings/0001493152-25-011910.md) | [19.0 d](/filings/0001493152-25-021287.md) | [0.0 d](/filings/0001493152-26-010102.md) | not reported | not reported | not reported | [15.0 d](/filings/0001493152-26-010102.md) | [2.0](/filings/0001493152-26-022276.md) | [3.0 d](/filings/0001493152-26-036424.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | thousands of shares | [2,941](/filings/0001140361-23-052742.md) | [5,127](/filings/0001140361-24-026010.md) | [5,303](/filings/0001493152-24-031639.md) | [5,410](/filings/0001493152-24-044841.md) | [5,410](/filings/0001641172-25-009044.md) | [361](/filings/0001493152-25-011910.md) | [361](/filings/0001493152-25-021287.md) | [142](/filings/0001493152-26-022276.md) | [207](/filings/0001493152-26-036424.md) | [8,226](/filings/0001493152-25-021287.md) | [792](/filings/0001493152-26-022276.md) | [1,183](/filings/0001493152-26-036424.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 1,632,411 at 2026-08-06, from the cover of the [10-Q filed 2026-08-06](/filings/0001493152-26-036424.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:23 ET. No prices; not investment advice.